International Scholarly Research Notices

Clinical Study

Resection and Immunotherapy for Recurrent Grade III Glioma

Table 3

Features of present and literature studies.


	Immunotherapy	Yung et al. [14]	van den Bent et al. [12]	Chinot et al. [10]	Balmaceda et al. [8]	van den Bent et al. [11]	van den Bent et al. [12]	Chang et al. [9]
Year of publication	Present study	1999	2003	2001	2008	2001	2003	2004

Study design	Retrospective single centre	Prospective multicentre phase II open label	Prospective multicentre phase II open label	Prospective single centre phase II open label	Prospective Multicentre Phase II Open arm	Prospective	Prospective multicentre phase II	Single centre open label

Study population	AA + AOA + AOD	AA+AOA	AOD	AOD + AOA	HGG	AOD + AOA	AOD + AOA	HGG

patients	39 (18 AA, 13 AOD, 8 AOA)	162 (AA = 111)	28	48 (AOD = 39)	120 (AA = 28, AOD = 24)	30 (AOD = 22)	39 (AOD = 24)	213 (AA = 53, AOA = 17)

TMZ protocol	/	150–200 mg/m² 5 d/28 d until 2 y/progression	150 mg/m² 5 d/28 d 6 cycles	150–200 mg/m² 5 d/28 d until 2 y/progression	1 × 200 mg/m² 9 × 90 mg/m² repeat every 28 d until 20 m/progression	150–200 mg/m² 5 d/28 d 12 cycles	200 mg/m² 5 d/28 d 12 cycles	150–200 mg/m² 5 d/28 d until 1 y/progression

N events	2 or more	2	NS	NS	Max 3	NS	NS	Any

Surgery at relapse	All patients	NA	+^§	NA	NA	+^§	+^§	NA

6 months PFS (%)	AA = 37.5 AOD = 33.3	AA = 49	AOD = 29	51*	AA = 50/AOD = 58	Responding = 44*	71°*	41*

12 months PFS (%)	AA = 37.5 AOD = 25	AA = 24	AOD = 11	25*	AA = 33/AOD = 42	Responding = 27*	40°*	NA

median PFS (m)	AA = 4.45 AOD = 4	AA = 5.5	AOD = 8	NA	AA = 6/AOD = 8	NA	Total = 10.4* Responding = 13.2*	5.3*

6 months OS (%)	AA = 94.2 AOD = 92.3	AA = 78	NA	77*	AA = 86/AOD = 75	NA	NA	75*

12 months OS (%)	AA = 76.5 AOD = 77	AA = 56	NA	46*	AA = 59/AOD = 71	NA	NA	NA

median OS (m)	AA = 20.5 AOD = 18.8	AA = 14.2	AOD = 12	10*	AA = 14.6/AOD = 18	Responding = 7*	Not yet reached*	12.3*

Grade III-IV toxicity

Hematological (%)	No	Lymphopenia: 6 Neutropenia: 2 Leukopenia: 2 Anemia: 1	Granulopenia and/or thrombocytopenia: 7.1	Thrombocytopenia: 6.4	18	Lymphopenia: 13.3	Granulopenia and/or thrombocytopenia: 25.6	25

Infection (%)	No	NA	NA	NA	NA	NA	2.6	NA

Nausea/vomiting (%)	no	12	10.7	NA	NA	6.7	5.1	4

Hepatotoxicity (%)	No	NA	NA	NA	NA	3.3	NA	1

Fatigue (%)	No	6	NA	17	NA	NA	NA	4

Others	No	Edema (1%) Fever (2%) Convulsions (5%) Headache (5%)	Dysphagia	NA	2 deaths	NA	NA	Allergy

AA: anaplastic astrocytoma; AOD: anaplastic oligodendroglioma; AOA: anaplastic oligoastrocytoma; NS: nonspecified; NA: not available; PFS: progression-free survival; OS: overall survival;
*: no subgroup details; °: not clarified whether results are from total or responding group; ^§: % patients that underwent surgery and % of total resection not available.